Duragesic Competition Could Add To Mylan’s “Authorized” Generics Fight
Executive Summary
The anticipated launch of an "authorized" generic of J&J's Duragesic could give Mylan further ammunition in its ongoing fight against such products
You may also be interested in...
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree
Congress will likely have to look at the issue of "authorized" generics, Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) said during an Oct. 6 Drug & Device Dialogue audio conference sponsored by FDC Reports and Polidais LLC